Replies to post #38673 on $heff's $tation of $tocks & $olid DD

[oldberkeley]

ABT scientists and execs are not stupid; as many have pointed out, the timing of their announcement certainly suggests that they feel approval is likely and they wanted to put their cards on the table now.

Many, many bios with good, approved drugs; unfortunately, the market says, "That's nice. Now how are you going to sell it?"

That's DEPO's problem here.

[DewDiligence]

…with the FDA giving Orphan Drug Status, it's pretty clear they are on board too.

An FDA Orphan Designation is all but assured when a drug candidate addresses a US market of fewer than 200,000 patients—it is not an FDA vote of confidence in the drug.